Intellia Therapeutics, Inc.
NTLAFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
58
Cost of Revenue
10
Gross Profit
48
Gross Margin
82.2%
Operating Income
-534
Operating Margin
-923.1%
Net Income
-519
Net Margin
-896.8%
EPS (Basic)
$-5.25
EPS (Diluted)
$-5.25
EBITDA
-524
EBITDA Margin
-905.3%
2023
12/31/2023
Revenue
36
Cost of Revenue
9
Gross Profit
27
Gross Margin
75.3%
Operating Income
-515
Operating Margin
-1420.5%
Net Income
-481
Net Margin
-1326.5%
EPS (Basic)
$-5.42
EPS (Diluted)
$-5.42
EBITDA
-506
EBITDA Margin
-1395.8%
2022
12/31/2022
Revenue
52
Cost of Revenue
8
Gross Profit
45
Gross Margin
85.5%
Operating Income
-458
Operating Margin
-879.0%
Net Income
-474
Net Margin
-909.8%
EPS (Basic)
$-6.16
EPS (Diluted)
$-6.16
EBITDA
-451
EBITDA Margin
-864.5%
2021
12/31/2021
Revenue
33
Cost of Revenue
7
Gross Profit
26
Gross Margin
79.2%
Operating Income
-268
Operating Margin
-810.4%
Net Income
-268
Net Margin
-810.5%
EPS (Basic)
$-3.78
EPS (Diluted)
$-3.78
EBITDA
-261
EBITDA Margin
-789.5%
2020
12/31/2020
Revenue
58
Cost of Revenue
150
Gross Profit
-92
Gross Margin
-159.4%
Operating Income
-137
Operating Margin
-235.5%
Net Income
-134
Net Margin
-231.5%
EPS (Basic)
$-2.40
EPS (Diluted)
$-2.40
EBITDA
-130
EBITDA Margin
-224.6%